Rep. Cliff Bentz Purchases Shares of Amgen Inc. (NASDAQ:AMGN)

Representative Cliff Bentz (R-Oregon) recently bought shares of Amgen Inc. NASDAQ: AMGN. In a filing disclosed on July 09th, the Representative disclosed that they had bought between $1,001 and $15,000 in Amgen stock on June 6th. The trade occurred in the Representative's "CHARLES SCHWAB SEP-IRA" account.

Representative Cliff Bentz also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Procter & Gamble NYSE: PG on 6/6/2025.

Amgen Trading Down 1.2%

Amgen stock opened at $294.76 on Friday. The stock has a 50-day moving average of $285.90 and a two-hundred day moving average of $289.35. The company has a debt-to-equity ratio of 8.70, a quick ratio of 0.88 and a current ratio of 1.17. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The stock has a market cap of $158.50 billion, a PE ratio of 26.89, a price-to-earnings-growth ratio of 2.66 and a beta of 0.49.

Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, beating the consensus estimate of $4.18 by $0.72. Amgen had a return on equity of 176.11% and a net margin of 17.39%. The business had revenue of $8.15 billion for the quarter, compared to the consensus estimate of $8.05 billion. During the same quarter last year, the business posted $3.96 earnings per share. The business's quarterly revenue was up 9.4% compared to the same quarter last year. On average, research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Institutional Trading of Amgen

A number of hedge funds and other institutional investors have recently modified their holdings of the business. EWA LLC acquired a new position in Amgen in the second quarter worth about $222,000. Access Financial Services Inc. grew its stake in Amgen by 3.6% in the second quarter. Access Financial Services Inc. now owns 3,925 shares of the medical research company's stock worth $1,096,000 after purchasing an additional 137 shares in the last quarter. Warren Street Wealth Advisors LLC grew its stake in Amgen by 506.7% in the second quarter. Warren Street Wealth Advisors LLC now owns 5,594 shares of the medical research company's stock worth $1,562,000 after purchasing an additional 4,672 shares in the last quarter. Naples Global Advisors LLC grew its stake in Amgen by 2.1% in the second quarter. Naples Global Advisors LLC now owns 35,186 shares of the medical research company's stock worth $9,824,000 after purchasing an additional 711 shares in the last quarter. Finally, Parsons Capital Management Inc. RI boosted its stake in Amgen by 1.0% in the second quarter. Parsons Capital Management Inc. RI now owns 21,565 shares of the medical research company's stock valued at $6,021,000 after acquiring an additional 215 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

AMGN has been the subject of several recent analyst reports. Piper Sandler reissued an "overweight" rating and set a $328.00 target price on shares of Amgen in a research note on Friday, June 27th. Morgan Stanley reaffirmed an "equal weight" rating on shares of Amgen in a research note on Friday, May 2nd. UBS Group reaffirmed a "neutral" rating and issued a $315.00 price objective (down from $319.00) on shares of Amgen in a research note on Friday, May 2nd. Erste Group Bank cut Amgen from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 8th. Finally, William Blair reaffirmed an "outperform" rating on shares of Amgen in a research note on Tuesday, June 24th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $307.82.

Insider Buying and Selling

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of Amgen stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total value of $434,520.00. Following the completion of the transaction, the senior vice president directly owned 8,162 shares in the company, valued at $2,364,368.16. The trade was a 15.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.76% of the stock is currently owned by insiders.

About Representative Bentz

Cliff Bentz (Republican Party) is a member of the U.S. House, representing Oregon's 2nd Congressional District. He assumed office on January 3, 2021. His current term ends on January 3, 2027. Bentz (Republican Party) is running for re-election to the U.S. House to represent Oregon's 2nd Congressional District. He declared candidacy for the 2026 election. Cliff Bentz graduated from Regis High School in 1970. Bentz earned a degree in history and business from Eastern Oregon State College in 1974 and a J.D. from Lewis and Clark Law School in 1977. His career experience includes working as a partner with the Yturri, O'Kief, Rose, and Burnham law firm. Bentz served as a board member and the vice chair of Project Dove.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.